The single-arm phase II study evaluating pomalidomide-plus-dexamethasone for relapsed/refractory multiple myeloma and phase II study evaluating pomalidomide-bortezomib-dexamethasone for the patients who are not able to achieve PR after pomalidomide-plus-dexamethasone therapy

Trial Profile

The single-arm phase II study evaluating pomalidomide-plus-dexamethasone for relapsed/refractory multiple myeloma and phase II study evaluating pomalidomide-bortezomib-dexamethasone for the patients who are not able to achieve PR after pomalidomide-plus-dexamethasone therapy

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms J-MEN 010 Study
  • Most Recent Events

    • 03 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top